

Request a meeting today!

PeerView Live

ONCOLOGY

CME

Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer

Rationale, Evidence, and Clinical Implications

Activity Overview

In the context of a small, interactive group discussion, hear an expert overview on PARP inhibition in prostate cancer. DNA repair defects in prostate cancer and the underlying mechanism of PARP inhibition—alone and in combination with other agents—play an important role in the management of metastatic castration-resistant prostate cancer (mCRPC). Furthermore, PARP inhibitors have shown evidence of efficacy for mCRPC and have been recently approved or are under review by the FDA. In this overview, hear about those PARP inhibitors and get insight into the rationale for and mechanisms of targeting DNA repair deficiencies in prostate cancer, practical considerations associated with genetic testing, evidence on the efficacy and safety of PARP inhibitors, and considerations for appropriate and effective integration of PARP inhibitor therapy for prostate cancer management. Request a meeting today!

3 Key Reasons to Request Meeting

1. Learn about companion diagnostic tests used to detect germline and somatic mutations when characterizing prostate cancer
2. Hear the efficacy data for PARP inhibitors recently approved or under review by the FDA for mCRPC
3. See how an expert identifies patients for clinical trials in prostate cancer

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, and other clinicians involved in the management of prostate cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Describe the rationale for therapeutic targeting of DNA repair defects and the mechanism of PARP inhibition in managing *BRCA*-mutant prostate cancer
- Review companion diagnostic tests that detect germline and somatic mutations within the DNA repair pathways
- Discuss the latest evidence with PARP inhibitors in advanced prostate cancer harboring DNA repair defects
- Identify patients with prostate cancer who may be candidates for clinical trial based therapeutic approaches, including studies testing combination regimens with PARP inhibitor components

CHAIR & PRESENTER

Emmanuel Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University School of Medicine
Baltimore, Maryland

For a complete faculty list, contact meetings@PeerView.com

For more details and to request your meeting today, visit: **PeerView.com/PARPLive**

Providership, Credit, and Support

Physician Continuing Medical Education:

Medical Learning Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, Inc., and Merck & Co., Inc.



REQUEST A MEETING FORM

Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer

Rationale, Evidence, and Clinical Implications

To request a meeting, please complete this form and return via email to meetings@PeerView.com, or fax to 1.877.380.6639. You may also complete this request online at **PeerView.com/PARPLive**

Chapter

Available Dates

Available Times (1-hour time slots)

AUDIENCE TOTAL AND BREAKDOWN (Please add the estimated total of each speciality below.)

_____ Urologists

_____ Oncologists

_____ Other MDs (Specify): _____

Other: _____

CONTACT INFORMATION

Primary Host Contact

Address

City | State | Zip

Primary Contact Phone | Primary Contact Fax

Primary Contact Email

OTHER COMMENTS / TOPICS OF INTEREST (Please list below.)

Select the Appropriate CME Provider Option:

- ○ Our chapter is an accredited provider and will provide credit for this activity.
- ○ Medical Learning Institute, Inc., in conjunction with PVI, will provide credit for this activity.

This CME activity is provided by Medical Learning Institute, Inc.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, Inc., and Merck & Co., Inc.